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results of the Artificial Pancreas Control (APC) study in progress at Oregon Health and 
Sciences University; this thesis will present results from the first seven subjects of the 
APC study. Hardware errors, failed infusion sites, and early termination of individual 
subject studies make for a small sample size, and thus insignificant results. However, 
closed loop technology is promising, and once the APC study is completed it will act as 
a guide for future research in the field. Artificial pancreas technology is ever moving 
forward, and will eventually create a device or system that allows type 1 diabetics to 
live without constantly thinking of diabetes care and blood glucose control.   
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Introduction 
There are twenty-six million people living with diabetes mellitus in the United 
States. Of these twenty-six million, twenty-three million are living with type 2 diabetes, 
which is characterized by insulin resistance primarily due to genetics with lifestyle and 
diet components. The other three million are living with a disease characterized by 
insulin deficiency, related to genetic risk and other unknown causes: type 1 diabetes 
mellitus (DM1). DM1 is an autoimmune disease that occurs when the insulin-producing 
cells of the pancreas are destroyed by a person’s immune system, causing patients to 
rely on synthetic insulin to be taken subcutaneously1 through injections or via an insulin 
pump. 
 Many advances have been made in the treatment and management of DM1. In 
the 1960s, type 1 diabetic patients had to rely on urine testing for blood glucose 
measurements and multiple-use glass needles to administer insulin.  The 1970s 
introduced the first blood glucose meter, and with the late ‘70s came the first insulin 
pump—a large device that had to be carried in a backpack (Hurley, 2010). As 
technology continued to improve, medical devices became smaller, more convenient, 
and more accessible to the public. Now, there are many different insulin pumps and 
devices called continuous glucose monitors2. DM1 control has become decreasingly 
invasive and increasingly user-friendly, allowing DM1 patients to spend less time 
thinking about calculations and numbers.  
 Currently, all methods of DM1 control are known as “open-loop” systems, 
meaning that a patient or caregiver must input information in order for the system to                                                         1 Under the skin 2 Devices that measure interstitial fluid glucose levels and display them in real time 
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work properly. However, clinical trials are being completed on “closed-loop” systems3 
(systems that take information and determine the amount of insulin or glucagon to 
deliver). The purpose of these systems is ultimately to replicate the mechanisms of a 
working pancreas in non-diabetic individual.  
 This thesis will present a brief background of type 1 diabetes mechanisms and 
current known control methods, as well as the design of the closed loop system that is 
currently being tested under the guidance of Dr. Jessica Castle and Dr. Peter Jacobs of 
the Harold Schnitzer Diabetes Center at Oregon Health and Sciences University. The 
results that are presented are preliminary results (subjects 001-004, 006-007) of the 
ongoing Artificial Pancreas Control (APC) study. 
                                                        3 Also known as an artificial pancreas 
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Background 
Type 1 diabetes history and mechanisms   The word diabetes comes from a Greek word meaning “to pass through.” This 
refers to one of the cardinal signs of diabetes: frequent urination. Later, the word 
mellitus was added to the title. Mellitus is the Latin word for “honey-like,” which 
referred to the taste of diabetic patients’ urine. It wasn’t until the late 19th century that 
diabetes mellitus type 1 was associated with the pancreas. Prior to the discovery of 
insulin by Frederick Banting and James Macleod in 1921, DM1 patients controlled their 
health by adopting a starvation diet at the recommendation of their doctors, and would 
not eat until their urine tested free of sugar (Hurley, 2010). Prior to the creation of blood 
glucose monitors, urine was tested either by the appearance, the taste, or urine strips 
that would turn a different color depending on the level of glucose (Hurley, 2010; 
Daneman, 2006). DM1 patients that underwent the starvation diet were in constant 
ketoacidosis, and were bed-ridden until they passed away at a young age. The starvation 
diet did not treat DM1, instead, it served to prolong a patient’s life until the cellular 
starvation became to be too much for the body tissues to handle (Hurley, 2010).   
 Type 1 diabetes results from cell-mediated autoimmune destruction of the beta 
cells—insulin-producing cells—of the pancreas. There are many possible 
autoantibodies4 that can be found in a DM1 patient, including islet cell5 autoantibodies, 
insulin autoantibodies, glutamic acid decarboxylase (GAD65) autoantibodies, and 
                                                        4 A “marker” that immune cells use to signal the destruction of tissues 5 Islet cells contain both beta (insulin-producing) and alpha (glucagon-producing) cells 
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tyrosine phosphates IA-2 and IA-2β autoantibodies. A diagnosis DM1 occurs when one 
or more of these autoantibodies are present in an individual with fasting 
hyperglycemia6. The rate of beta cell destruction varies from patient to patient, but once 
severe hyperglycemia or ketoacidosis7 occurs, it is highly probable that insulin 
production has ceased and the patient must rely on the synthetic8 insulin administration 
(Daneman, 2006).  
  
Figure 1: A target cell (Kleck) 
This image outlines the effect that insulin has on cells in need of glucose. Once insulin 
binds to the insulin receptor, the cell goes through a cascade of reactions that ultimately 
leads to the GLUT-4 transporter translocating to the surface of the cell. This allows 
glucose to be pulled into the cell and be used for various energy-producing processes 
Insulin is required for all DM1 patients to stay healthy and maintain good blood 
glucose control. In a non-diabetic, insulin, an endocrine hormone is released from the 
beta cells of the pancreas when the pancreas detects a rise in blood glucose levels. It 
travels through the bloodstream and attaches to insulin receptors on muscle and tissue                                                         6 Fasting hyperglycemia occurs when an individual presents with a blood glucose of >126 mg/dL after fasting for at least eight hours 7 Ketoacidosis occurs when the body cannot use glucose as a fuel source and instead breaks down fat for energy, and produces ketones 8 Also known as insulin aspart 
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cells causing the target cell to go through a cascade of chemical reactions. This 
ultimately leads to the translocation of a GLUT-49 transporter to the cell surface. This 
translocation allows glucose to be pulled from the bloodstream into the cell to be used 
as energy (Roth & Zick, 2000). This mechanism works similarly in people with type 1 
diabetes, except that they must take insulin manually instead of producing it in their 
body.  
Current control methods for DM1 patients  Blood glucose control is the largest challenge that type 1 diabetics face. Since 
DM1 patients lack the detection and control physiology, they very rarely stay in a tight 
blood glucose range10. Instead, they must have a basal insulin dose—constant insulin, 
either through small increments in an insulin pump or by way of a long-acting insulin 
injection—as well as a bolus dose—doses for food or to correct hyperglycemia. The 
factors and dose amounts for insulin varies by patient and time of day, and must be 
calculated for each person. Typically, these ratios are entered into an insulin pump, but 
are occasionally written down and used for insulin injections. There are two standard 
ways of measuring blood glucose for DM1 patients: 1) using a blood glucose meter 
anywhere from 3 – 10 times daily, or 2) using a real-time continuous glucose monitor 
(CGM). A CGM works by measuring the glucose levels of the interstitial fluid that 
surrounds the platinum wire that is placed subcutaneously. These values are sent to a 
receiver every five minutes. While these methods have improved for blood glucose 
control over the years, they still require a large amount of thought on the DM1 patients’                                                         9 Glucose transporter-4 10 Normal blood glucose range for non-diabetics is defined as 70-100mg/dL 
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part. The ratios for insulin pumps or insulin injections must be calculated and kept up-
to-date, and outside information that could affect blood glucose levels must be 
accounted for.  
Patients with type 1 diabetes also fail to release glucagon, a peptide hormone 
that works to raise blood glucose. Glucagon is produced in the alpha cells of the 
pancreas, and in non-diabetics is released in small amounts when a drop in blood 
glucose is detected. Glucagon causes the liver to breakdown glycogen into glucose 
molecules, effectively raising blood sugar. DM1 patients must be administered 
glucagon when their blood glucose levels dip dangerously low. However, synthetic 
glucagon is not as stable as synthetic insulin. It must be mixed before administration, 
and it must be administered in large doses. Once glucagon is reconstituted, it is only 
viable for twenty-four hours. Thus, DM1 patients reserve glucagon treatment for 
extremely dangerous low blood glucose levels, and instead treat hypoglycemia or 
dropping blood glucose levels with oral glucose forms.  
Exercise and DM1 
Blood glucose can be affected by any number of factors11. Usually, each 
individual with type 1 diabetes responds uniquely to different stressors, but exercise is 
one that tends to have the same response across the board. This is due to the 
physiological response to the body’s need for energy when exercise begins. The body 
uses a few different energy substrates—muscle glycogen, plasma glucose, free fatty 
acids, and intramuscular triglycerides. When exercise begins, GLUT-4 receptors                                                         11 These factors can include different types of food, stress, excitement, and exercise. 
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translocate to the surface of the cell, much like they do when insulin is circulating the 
bloodstream. During exercise, this process is completed without insulin (Goodyear & 
Kahn, 1998). DM1 patients tend to become hypoglycemic during and after exercise. 
GLUT-4 receptors translocate whether or not insulin is present during exercise. If 
insulin is present, more receptors will translocate and pull more glucose from the 
bloodstream causing patients to experience hypoglycemia. Since DM1 patients also lack 
natural glucagon, they have no way of replacing the glucose that was used for energy 
(Derouich & Boutayeb., 2002). This increase in GLUT-4 receptor availability can last 
for hours after exercise, which increases the risk for post-exercise hypoglycemia. 
Existing research and practice in closed-loop systems 
Until recently, methods of treatments have been kept relatively separate from 
one another, and each treatment requires input from the patient or a caregiver. These 
systems are known as open-loop systems. Normally, DM1 control is maintained by 
frequent capillary blood glucose readings, continuous glucose monitors, insulin pumps, 
or insulin injections. By combining different medical devices with algorithms, 
researchers have been able to develop a closed-loop system that is able to take 
information such as a glucose reading, use predictive algorithms, calculate the amount 
of insulin or glucagon needed to maintain blood glucose measurements in a tight range, 
and carry out the dosing (Bakhtiani, et. al., 2013; El Youssef, et. al., 2009; Jacobs, et. 
al., 2011; Pevser, et. al., 2014).  
 There are two types of closed-loop systems: unihormonal and bi-hormonal 
systems. Unihormonal systems combine a CGM, insulin pump, and a controller with 
algorithms. This system works by giving insulin when needed, and suspending the 
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insulin pump when blood glucose falls. Once the CGM predicts a hypoglycemic 
episode, it sends information to the computer, which then notifies the insulin pump to 
suspend insulin for ninety minutes (Buckingham, et. al., 2009). The unihormonal 
system is efficient at preventing quick drops in blood glucose if the predictive alarm 
occurs far enough in advance and if the only cause for hypoglycemia is too much 
insulin. 
 Bi-hormonal systems integrate both glucagon and insulin into the set-up. By 
using two different hormones, these systems have been more successful at preventing 
impending hypoglycemia. Some studies  “utilize[s] control algorithms that alter output 
based on proportional (difference between actual and target levels), derivative (rate of 
change) and integral (time-related summative) errors in glucose” (Youssef, et. al., 
2009). In these systems, glucagon was given in smaller doses for smaller drops in blood 
glucose, and was generally successful at preventing hypoglycemia. However, there 
were some instances in which the doses of glucagon failed to prevent hypoglycemia. 
Most of these instances occurred when the subject already had a large amount of insulin 
in his or her bloodstream. A number of studies have proven that glucagon works less 
efficiently when insulin is still in the bloodstream (Bakhtiani, et. al., 2013; Castle, et. 
al., 2010). While insulin works to decrease blood glucose levels, glucagon works to 
increase blood glucose levels. If there is a large amount of insulin present, the glucagon 
will be working against the insulin action, and will not work as efficiently.  
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Artificial Pancreas Control design 
Study design 
The artificial pancreas control (APC) study uses two Tandem t:slim pumps, one 
Dexcom G4 sensor, and a Google Nexus 5 phone. The subject is outfitted with both 
pumps; one with insulin, inserted into the right side of the subject’s body, and one with 
Glucogen—a brand name for glucagon—inserted into the left side of the subject’s body. 
The subject is also paired with a Dexcom sensor (placed subcutaneously) and 
transmitter. The APC controller is the Google Nexus 5 phone, which runs the algorithm 
(discussed below). This phone is plugged into a battery case, and connected to the 
Dexcom G4 receiver. Every five minutes, the Dexcom receiver transmits its glucose 
reading to the algorithm in the phone, which runs calculations and will send insulin and 
Glucagen infusion commands to the respective T-slim pumps via Bluetooth (see figure 
2).  
For study purposes, the phone also communicates via the Cloud with other 
computers. It steadily uploads the data it calculates, as well as the sensed blood glucose. 
This data is then portrayed on a password-protected website that is viewable from any 
browser (IDE, 2014). 
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Figure 2: Study design (IDE, 2014) 
A schematic of the different components of the APC study and how they connect. 
Study algorithm 
The APC algorithm utilizes the fading memory proportional derivative 
controller (FMPD). The proportional portion of this algorithm measures the difference 
between the sensed blood glucose and the target blood glucose12,13. Positive 
proportional errors mean that sensed glucose levels are above target, and will cause the 
algorithm to calculate a larger amount of insulin to be infused. Negative proportional 
errors mean that sensed glucose is below target. The derivative error measures the 
amount of change in the sensed glucose, calculated over a ten-minute time interval. 
Positive derivative errors mean that the sensed glucose levels are rising, while negative 
derivative errors mean that sensed glucose levels are falling. The degree of the 
                                                        12 Daytime target blood glucose is set at 115 mg/dl. 13 Nighttime target blood glucose is set at 140 mg/dl.  
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derivative error indicates how quickly glucose levels are changing; a large derivative 
error will mean that sensed glucose levels are changing very fast.  
Blood glucose levels are maintained by the infusion rate of insulin; this rate can 
be increased or decreased by the algorithm if needed. However, this is also a bi-
hormonal closed-loop system, so glucagon can be used to raise falling or low blood 
glucose if needed (IDE, 2014; Jacobs, et. al., 2014).  
Insulin infusion 
The APC algorithm calculates three different types of insulin infusion rates, and 
adds them together for a total insulin infusion rate (IIRT, measured in units/hour). The 
first rate to be calculated is the basal rate (IIRB). This is a relatively constant value, and 
is calculated using 50% of the total daily insulin requirement (TDIR14) divided by 24. 
The IIRB is constant until blood glucose declines below target. When sensed glucose is 
below target, the IIRB is decreased until the sensed glucose reaches 60% of target 
glucose, at which point the IIRB is shut off. 
 The other two rates calculated are the proportional error insulin rate (IIRPE) and 
derivative error insulin rate (IIRDE). The IIRPE accounts for the difference between the 
target blood glucose and the sensed glucose level, while the IIRDE takes into account the 
rate of change of sensed glucose. The actual insulin infusion rates are affected by the 
gain multiplier, a multiplier that adjusts for differences in insulin sensitivity15.  There is 
also a fading memory component to the algorithm, which means that the algorithm                                                         14 In most cases, TDIR is taken as reported from the subject. However, for every percentage point above 7%, TDIR is increased by 6.67% to take into account poor blood glucose control and common hyperglycemia 15 The gain multiplier is calculated from the TDIR. The higher the TDIR, the higher the gain multiplier 
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gives more weight for recent proportional and derivative errors over past proportional 
and derivative errors.  
The IIRT is calculated by adding IIRB, IIRPE, and IIRDE together. The IIRT is the 
amount of insulin expected to be infused over one hour. However, it may change with 
subsequent data from the Dexcom sensor, so this value is divided by twelve and given 
over a five-minute period, to be adjusted with the next input of data.  
Meal boluses occur at the start of a meal. The amount of grams of carbohydrates 
for a given meal is input into the algorithm, and the algorithm calculates a bolus using 
the grams and TDIR. For the purposes of this study, only 60% of the expected meal 
bolus is given to the subject.  
Once insulin is infused, insulin on board (IOB) must be calculated and taken 
into account for future IIRT calculations. Insulin can stay active for hours after delivery. 
In this FMPD algorithm, IOB levels rise linearly for thirty minutes after delivery, then 
stay at a maximum level for sixty more minutes. Ninety minutes after delivery, IOB 
levels decrease exponentially. The IOB levels are calculated every five minutes, with 
each new IIRT. If the IOB rises above 10% of TDIR, the IIRT will be reduced. Once 
IOB reaches 30% of TDIR, IIRT will be reduced to 0 (IDE, 2014; Jacobs, et. al., 2014).  
Glucagon infusion 
Total glucagon infusion rate (GIRT)16 is calculated by adding the proportional 
error infusion rate (GIRPE) and the derivative error infusion rate (GIRDE). There is no 
basal glucagon. GIRPE takes into account the proportional errors that happened within 
                                                        16 measured in micrograms/hour 
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fifteen minutes prior to the time of calculation using the glucagon set points17. GIRDE 
takes into account the derivative errors that happened within ten minutes prior to the 
time of calculation. Both the GIRPE and GIRDE have the fading memory component. 
Once glucagon is delivered, it is expected to decay exponentially over time.  
The efficiency of glucagon at raising blood glucose is affected by insulin already 
in the system (IOB). Therefore, GIRT must be modified according to the IOB value. If 
IOB is low, then the maximum GIRT allowed can be low as well. If IOB is high, the 
maximum GIRT will be higher. GIRT in a fifty minute period can be up to 2.0 mcg/kg. 
If this maximum dose is fully delivered over fifty-minutes, two things will change in the 
algorithm. First, there will be a refractory period of fifty-minutes in which no glucagon 
can be delivered. Second, the IIRT will be decreased by 75% for forty minutes so as to 
give the glucagon an optimal environment to work in, and to avoid potential overdose 
of insulin (IDE, 2014; Jacobs, et. al., 2014). 
 
Exercise announcement programming 
There is an exercise announcement option in the algorithm as well. If used, it 
affects both IIRT and GIRT for one and a half hours after the initial start. The 
announcement should occur at the start of exercise, and is completed by pushing a 
button on the controller phone. From there, insulin is shut off for thirty minutes and 
then reduced by 50% for one hour, for a total change of 90 minutes.  
                                                        17 Glucagon set point is 95 mg/dl 
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Two changes occur in the glucagon calculations. First, the maximum dose 
allowed for glucagon is increased by the same parameters that are used when IOB is 
high. Second, the glucagon set point is increased, meaning that glucagon can be infused 
at a higher sensed glucose reading. Instead of an optimal set point of 95 mg/dl, exercise 
announcement sets an optimal set point of 110 mg/dl. Once these adjustments are made, 
they will be maintained for one and a half hours after the start of exercise (IDE, 2014; 
Jacobs, et. al., 2014). 
 
 
15 
 
Methods 
This study took place through the Harold Schnitzer Diabetes Health Center at 
the Hatfield Research Clinic (HRC) in Oregon Health and Sciences University (OHSU). 
It is designed to compare glucose control resulting from 1) open loop control, 2) a bi-
hormonal closed-loop system with exercise announcement and 3) a bi-hormonal closed-
loop system without exercise announcement. The following procedure is an outline of 
the APC Study Procedure used at OHSU, with extra information required for the 
purpose of this thesis. 
Subjects 
Subjects were adults between 18 – 45 years of age with type 1 diabetes. There 
were up to fifty subjects screened, with a goal of twenty-one subjects enrolled. Subjects 
must have a diagnosis of type 1 diabetes for at least 1 year, be willing and able to 
perform 45 minutes of exercise, and use an insulin pump at the time of screening. 
Subjects must not have met any exclusion criteria (Appendix A). Subjects were 
recruited from the OHSU website and clinics, as well as from past clinical trials 
completed under Drs. Castle or El Youssef. Subjects may also have been recruited by 
using the diabetes research registry and www.clinicaltrials.gov. 
For the purposes of this thesis, data was taken from subjects 001, 002, 003, 004, 
006, and 007 for analysis.  
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Procedure 
Subjects made seven total visits to OHSU’s Hatfield Research Clinic. These 
visits were made up of the screening process, three sensor insertion visits, and three 21-
hour treatment visits.  
Screening Process (visit 1) 
 Subjects first underwent a screening process. This process took place within 12 
weeks before visit 2. Consent forms were signed at this initial visit. Capillary blood 
glucose was measured and a venous blood sample was taken in order to measure 
HbA1c, complete blood count, complete metabolic panel, and c-peptide. An EKG was 
performed, and then subjects underwent VO2max testing18 if they met all inclusion 
criteria and no exclusion criteria.  
Sensor insertion (visits 2, 4, 6) 
 Subjects completed a sensor insertion visit no more than 72 hours before each 
treatment visit. Subjects were fitted with a DexcomTM G4 CGM and were trained on 
how to use and calibrate the CGM. The CGM was inserted into the subject’s abdomen 
or flank. 
21-hour treatment (visits 3, 5, 7) 
 Subjects were asked to avoid exercise for 24 hours prior to treatment visits. 
Subjects arrived at OHSU’s HRC at 8pm. For two of the three visits, the subjects 
underwent the closed-loop treatment. Upon arrival to the HRC, subjects were instructed                                                         18 This test was for the purpose of determining optimal exercise level; subjects exercised at 60% of their maximum heart rate. 
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to disconnect their own insulin pump, and instead used two Tandem Diabetes Care 
t:slim infusion pumps for the duration of the visit. One infusion pump was filled with 
aspart insulin, and the other with glucagon19. The subject was also in possession of a 
Google Nexus 5 phone, which ran the computerized FMPD algorithm every five 
minutes upon arrival of a new blood glucose reading from the Dexcom sensor. The 
Google Nexus 5 phone sent instructions wirelessly to the two t:slim pumps, as well as 
sent data to a cloud server every five minutes. Once the subject was fitted and 
comfortable with all devices, research staff left the subject’s room, but had access to the 
cloud data, as well as a chat device if they had any questions or concerns. The subject 
recorded any symptoms and occurrences in a journal. A research technician was 
monitoring the data and could intervene when necessary.  
The research technician calibrated the Dexcom sensor every six hours. The 
subject’s blood glucose readings were measured every two hours during the day and 
every three hours at night. This was a blind measurement, and subjects were not aware 
of their capillary blood glucose (CBG) measurements for the duration of the study, but 
could view the sensed glucose on the phone and/or Dexcom. When the subject ate20, the 
meal was announced to the Google Nexus 5 phone. 
In the morning after arrival at the research center, the subject ate breakfast at 
6am. Two hours after the meal, the subject exercised for 45 minutes on a treadmill at a 
fixed rate of 60% of their maximum heart rate21. One closed-loop treatment visit 
                                                        19 Glucagon will be reconstituted to a concentration of 1.0mg/mL using sterile water. 20 A low carbohydrate meal in which all carbohydrates were measured. 21 Determined from the VO2max test at the screening visit 
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included an exercise announcement to the controller. The other closed-loop treatment 
visit did not include an exercise announcement. Three hours after exercise, the subject 
ate lunch. Five hours after lunch the closed-loop system was terminated, the two t:slim 
pumps and Dexcom sensor were removed, and the subject was released.  
The other 21-hour treatment visit consisted of an open-loop treatment. During 
this visit, subjects wore the Dexcom sensor, but managed their own blood glucose 
control. There was no suggested protocol for preparing for exercise; subjects were 
allowed to change their basal rates and meal boluses in order to prepare for exercise. 
If the sensed blood glucose fell below 70 mg/dl at any point in the study, a CBG 
measurement was taken and rescue carbohydrates were given if needed. If the sensed 
glucose fell below 50 mg/dl at any point in the study, the visit was terminated and the 
subject was asked to reschedule and start that particular visit over. If the sensed glucose 
rose above 300 mg/dl, a CBG measurement was taken, ketone levels were measured (if 
needed), and termination was considered for that visit.  
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Hypothesis 
It is expected that the closed-loop system with exercise announcement will be 
more successful at preventing hypoglycemia during and after exercise than the closed-
loop system without exercise announcement and the open loop system. It is also 
expected that both closed loop systems will present with tighter blood glucose control 
(i.e. a smaller standard deviation and a higher percentage between 75-180 mg/dl) than 
the open loop system. 
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Results 
There was a total of five participants in the open loop and closed loop portion of 
the study, and six participants in the closed loop with exercise announcement. The 
average blood glucose reading over nine hours (one hour prior to the start of exercise, 
and eight hours following the start of exercise) for the open loop condition (OL) was 
161.6±54 mg/dl. The average blood glucose reading for the closed loop condition (CL) 
was 152.4±47.8 mg/dl. The average blood glucose reading for the closed loop with 
exercise announcement condition (CLX) was 154.6±47.8 mg/dl. Further study into the 
results and trends follows. 
The following three graphs show individual subjects’ sensed blood glucose 
readings over time with the average blood glucose reading (and standard deviation) over 
time overlaid. The fourth graph is the average sensed blood glucose readings over time 
from each different condition.  
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Figure 3: Open loop graph 
This graph is the compiled data from the open loop portion of the study. Each black line 
represents the raw data of a study participant; the blue line represents the average blood 
glucose readings of each five-minute increment. The red portion of the graph represents 
hypoglycemia, the green portion represents target blood glucose, and the orange portion 
represents hyperglycemia. The purple portion of the graph represents the time the 
subject was exercising. 
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Figure 4: Closed loop graph 
This graph is the compiled data from the closed loop portion of the study. Each black 
line represents the raw data of a study participant; the blue line represents the average 
blood glucose readings of each five-minute increment. The red portion of the graph 
represents hypoglycemia, the green portion represents target blood glucose, and the 
orange portion represents hyperglycemia. The purple portion of the graph represents the 
time the subject was exercising. 
   
 
 
23 
 
Figure 5: Closed loop with exercise announcement graph 
This graph is the compiled data from the closed loop with exercise announcement 
portion of the study. Each black line represents the raw data of a study participant; the 
blue line represents the average blood glucose readings of each five-minute increment. 
The red portion of the graph represents hypoglycemia, the green portion represents 
target blood glucose, and the orange portion represents hyperglycemia. The purple 
portion of the graph represents the time the subject was exercising. The line enclosed 
by a triangle and diamond represents the portion of time that the exercise 
announcement algorithm changes were in effect.  
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Figure 6: Average blood glucose over time 
This graph shows the average blood glucose of each time increment, for each separate 
study condition.  
The parameters for evaluation of the success of this study were the percent of 
time in target range (75-180 mg/dl), the percent of time spent in hypoglycemia (below 
75 mg/dl), and the percent of time spent in hyperglycemia (above 180 mg/dl). These 
measurements were taken from the raw data, not the average trends. The following table 
shows these percentages for each component of the study, as well as overall average 
blood glucose reading and the standard deviation from that average. 
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Figure 7: Table of percentages 
For the OL portion of the study, data from subjects 001, 002, 004, 006, and 007 
was used. For the CL portion of the study, data from subjects 002, 003, 004, 006, and 
007 was used. For the CLX portion of the study, data from subjects 001, 002, 003, 004, 
006, and 007 was used. A paired t-test using complete data sets (subjects who 
completed all three portions of the study) was completed first. The following t-tests 
measured the significance of the percent of time that each subject was hypoglycemic 
(figure 8). 
 
 
 
 
 
 
Figure 8: Fraction of time spent in hypoglycemia per subject 
This table represents the fraction of time that each subject spent in hypoglycemia. 
Subject 001 did not complete the closed loop portion of the study, and subject 003 did 
not complete the open loop portion of the study.  
The p-value of a paired, two-tailed t-test comparing the OL and CL portions of 
the study was 0.36. The p-value of a paired t-test comparing the OL and CLX portions 
of the study was 0.54. The p-value of a paired t-test comparing the CL and CLX was 
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0.98. Because there were only four subjects with complete data sets, unpaired t-tests 
were also completed. An unpaired t-test comparing the OL and CL portion of the study 
resulted in a p-value of 0.57. An unpaired t-test comparing the OL and CLX portion of 
the study resulted in a p-value of 0.57. An unpaired t-test comparing the CL and CLX 
resulted in a p-value of 0.55.  
The secondary parameters used to measure the success of this study included the 
standard deviation of each subject, and the percent of time spent in target range (75-180 
mg/dl) for each subject. 
The p-value for an unpaired t-test comparing the standard deviations from the 
OL and CL portions of the study was 0.73. The p-value for an unpaired t-test comparing 
the standard deviations from the CL and CLX portions of the study was 0.84. The p-
value for an unpaired t-test comparing the standard deviations from the OL and CLX 
portions of the study was 0.84.  
The percent of time spent in target range for each subject was measured as well. 
 
Figure 9: Percent of time spent in target (75-180 mg/dl) range 
The p-value for an unpaired t-test comparing the fraction of time spent in target 
range between the OL and CL portions of the study was 0.06. The p-value comparing 
the same measurements between the CL and CLX portions of the study was 0.30. The 
p-value comparing the OL and CLX portions of the study was 0.17. 
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Discussion 
These results are preliminary results of the Artificial Pancreas Control study that 
is in progress at Oregon Health and Sciences University. None of the results are so far 
significant (p>0.05)22, but there is good direction for the remainder of the APC study. 
Both the closed loop (CL) system and the closed loop with exercise announcement 
(CLX) system seem to be efficient at avoiding hypoglycemia during exercise. However, 
after exercise there were a few more hypoglycemic instances in the CL portion of the 
study than the CLX portion of the study. This wasn’t proved to be significant by the 
data, but it does show that the decrease of insulin and increase of glucagon by the 
exercise announcement has a long-term effect for the hours after exercise. During 
exercise, there is insulin- and noninsulin- mediated glucose uptake into cells for energy 
use. If insulin is present in a DM1 patient in the bloodstream, it will be used to facilitate 
glucose transport into cells, regardless of falling blood glucose levels (Briscow, et. al., 
2007). The exercise announcement algorithm decreases the amount of insulin (basal and 
extra) given during the programmed duration, and thus lowers the amount of insulin 
available for cells to use to transport glucose.  
 By increasing the maximum amount of glucagon dosage allowed during the 
exercise announcement program, hypoglycemia was avoided. In DM1 patients, the 
typical response to falling blood glucose levels are blunted; glucagon, epinephrine, 
norepinephrine, growth hormones, and lipolysis all occur in non-diabetics. Many of 
these hormones fail to respond, or respond weakly, when a DM1 patient becomes 
hypoglycemic. It was found, however, that the hormone response for a single episode of                                                         22 Reasons for insignificance will follow this section 
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hypoglycemia was much greater when there were no hypoglycemic episodes in the 
twenty-four hours prior. When multiple hypoglycemic episodes occurred, the hormone 
response was significantly lower (Briscow, et. al., 2007). Preventing hypoglycemia in 
the APC study gives the body a chance to reserve its strong hypoglycemic response for 
a later episode, and by increasing the maximum amount of glucagon allowed, 
hypoglycemia during exercise is less likely to happen. 
It was also expected that both closed loop systems would allow for tighter 
control (i.e. a smaller standard deviation and a higher percentage of time spent in target 
range, 75-180 mg/dl) when compared to the open loop system. While neither of these 
parameters showed statistical significance (p>0.05), it is important to explore why 
control may be different across systems.  
Open loop control is typically predictive or reactive, especially when a patient is 
able to view their blood glucose levels constantly23. Many DM1 patients are used to 
experiencing hypoglycemia during and after exercise, so they consciously make 
changes so that their blood glucose levels run higher than normal. This will result in 
higher average blood glucose and less time spent in target range. Open loop control 
essentially puts a human (the subject) in control of the system. While DM1 patients 
have many ratios24 calculated specifically for their own insulin needs, there is always 
room for error and miscalculations. Human error in the open loop systems can result in 
large fluctuations in blood glucose, or extended period of time out of target range.  
                                                        23 As with the CGM used in the APC study 24 Such as insulin to carb, correction factors, and set basal rates 
 
 
29 
 
Closed loop systems, however, have minimal human input. Calculations for 
insulin dosing are taken directly from the algorithm, and are all numerically based; the 
only human input occurs when announcements (such as the exercise announcement) are 
made to the algorithm. This is a much more precise way of calculating insulin dosing, 
and requires no outside thought. The closed loop system is reactive as well, but in a 
different way than the open loop system. In an open loop system, a DM1 patient may 
see that their blood glucose levels are falling, and decide to temporarily decrease the 
amount of basal insulin they receive by a large amount to avoid potential hypoglycemia. 
However, a closed loop algorithm would detect a decrease in blood glucose levels, 
would gradually decrease the insulin infusion rate as the blood glucose levels change, 
and then begin to gradually increase the insulin infusion rate as the blood glucose levels 
become steady. In the open loop scenario, the DM1 patient has the danger of 
rebounding with hyperglycemia due to too little insulin from the decreased basal rate. In 
the closed loop scenario, the system is able to adjust as the blood glucose levels change. 
This would result in a greater percent of time spent in target range, and less blood 
glucose fluctuations.  
The tendency of open loop control to result in higher average blood glucose 
levels can become dangerous after a while. Because hypoglycemia is an immediate 
danger, some DM1 patients prefer to maintain a higher average blood glucose. High 
blood glucose, along with large fluctuations that are common in open loop systems, 
presents the danger for complications in later life. Nephropathy, retinopathy, and other 
nerve problems are common in older patients who have been dealing with DM1 for a 
number of years. Non-diabetic patients have protection at a cellular level against 
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hyperglycemia. When blood glucose levels become high, cells that are exposed to the 
blood stream are able to reduce the rate of glucose transport, so that cellular glucose 
levels remain at a normal level. In a DM1 patient, this mechanism to protect the cells is 
damaged. Hyperglycemia does not cause a change in glucose transport into the cells. In 
fact, because DM1 patients tend to have a large amount of insulin circulating when their 
blood glucose levels are high, it is likely that cellular glucose levels are high as well. 
Long-term exposure to high cellular glucose levels leads to cell damage, and the regular 
mechanisms are unable to function (Brownlee, 2005). This is why it is important to 
avoid hyperglycemia, as well as hypoglycemia. In the APC study, hyperglycemia was 
not prevented, and occurred throughout each condition. The closed loop systems 
presented a lower average blood glucose reading, but still had some incidences of 
hyperglycemia. This could be due to the meals; the insulin used in the study can take up 
to thirty minutes to work. While the system was calculating the amount of insulin 
needed for a meal, the subjects’ bodies were reacting to the meal before the insulin. 
This could also be due to glucagon infusion. While glucagon was being infused in very 
small rates, there is a variance across the population to glucagon sensitivity. Some 
subjects were very sensitive to glucagon, and experienced hyperglycemia after a few 
doses. Others required a larger amount of glucagon to prevent hypoglycemia.  
There were a number of limitations during the first subject studies that could 
affect results. First was a hardware problem. If the controller happened to run out of 
battery power, it was unable to recover the study after crashing. This happened with two 
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subjects (00525 and 001), which caused a gap in the raw data. One other subject 
experienced a failed pump infusion site, and received no insulin for an extended amount 
of time. This would result in extreme hyperglycemia. Finally, disruptions could occur at 
any communication point (controller, Dexcom, or pump), and could skew data.   
                                                        25 The hardware problem occurred at subject 005’s first visit, so none of the data was used from subject 005.  
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Conclusion and Future Research Directions 
The challenge with closed-loop systems is that the final product must be able to 
replicate the mechanisms of a working organ. A pancreas in a non-diabetic is able to 
immediately detect small changes in blood glucose, and release the exact amount of 
insulin (or glucagon) required to maintain a homeostatic level. These hormones work 
quickly, since they are released directly into the blood stream. At any given time, a 
blood glucose reading from a non-diabetic is likely to read between 80 and 100 mg/dl. 
This is an extremely small window for error, and the human body is well practiced at 
maintaining blood glucose levels within this range.  
It is the perfection of the human body that makes it so difficult to duplicate with 
machines. A working continuous glucose monitor is very good at recognizing trends, 
but can lag behind quick blood glucose level changes by up to half-an-hour. A CGM 
that isn’t working great may still display readings, but can be 100 mg/dl off from the 
actual level. The action time of synthetic insulin has become quicker since the invention 
of insulin, but it can still take up to thirty minutes to show an effect on blood glucose.  
Outside effects on blood glucose are variable as well. Stress and adrenaline may 
cause one DM1 patient to experience hypoglycemia, and another DM1 patient to 
experience hyperglycemia. The insulin sensitivity of DM1 patients can change over 
time with age and weight. While 15 grams of carbohydrates may raise one individual’s 
blood glucose by 50 mg/dl, it could raise another individual by 100 mg/dl. The effects 
of everyday life have extremely variable effects on blood glucose by patient, and even 
over time in a single patient. A non-diabetic pancreas can easily manage all the 
biological differences between patients, but a machine will have much more difficulty.  
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These systems have proven to be successful in maintaining a target blood 
glucose reading for long periods of time, preventing hypoglycemia after an overdose of 
insulin, preventing nocturnal hypoglycemia, preventing hyperglycemia after meal 
announcements, and detecting and estimating meals after failure to bolus (Lee, et. al., 
2009; Bakhtiani, et. al., 2013; Buckingham, et. al., 2009; Jacobs, et. al., 2011; Peyser, 
et. al., 2014). However, there is still a long way to go. A quicker-acting form of insulin 
must be developed before closed-loop systems are able to replicate the pancreas.  The 
current form of synthetic glucagon decays at an exponential rate after being 
reconstituted. This is not stable enough to be used in a closed-loop system for a long 
period of time. Algorithms for such systems must be able to take into account all the 
variance that a DM1 patient may experience and adjust for major changes. 
Artificial pancreas studies are currently being completed at research hospitals 
throughout the United States. There are many different types of closed-loop systems 
that have varying levels of success. Some are unihormonal, and some are bi-hormonal. 
The first system to have success was created by a father of a type 1 diabetic son; other 
systems are being created at the hands of teams of engineers and doctors. There are 
closed loop systems that are popping up out of the woodwork; some are labeled as “do-
it-yourself” closed-loop systems, and families are encouraged to test the efficacy of the 
system at their own risk (Hoskins, 2015). With the successful completion of each study, 
the world will be one step towards a complete artificial pancreas system. Every 
component of DM1 control must be taken into account and represented in the final 
closed-loop algorithm.  
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With the anticipated completion of the APC study at OHSU, researchers will 
have a better frame of reference and understanding of how a closed-loop algorithm can 
work to prevent expected hypoglycemia during and after exercise. Whether or not the 
final study results are significant, they will help future studies to fine-tune errors and 
work towards the end goal of a fully successful closed-loop system.  
Current control methods are adequate for blood glucose control. Many DM1 
patients have been surviving for years using blood glucose meters, continuous glucose 
monitors, insulin pumps, and even daily insulin injections. However, adequate does not 
mean easy. To maintain tight blood glucose control, DM1 patients must be constantly 
aware of how their blood glucose levels are changing and how their daily activities 
will—or could—affect these levels. Many patients who have been dealing with DM1 
for a number of years also face a myriad of other complications such as nephropathy, 
neuropathy, retinopathy, and other nerve or organ diseases. While these complications 
can stem from poor control, most often they stem from the natural blood glucose swings 
that every DM1 patient experiences at some point in their life. The release of a closed-
loop system to the medical market will help to decrease the amount of involvement that 
DM1 patients must have in their blood glucose control, and will also decrease the risk 
for complications that many DM1 patients face. While many DM1 patients are already 
adequately controlling their blood glucose levels, this system will help to free them 
from the constant worry and preoccupation that comes with type 1 diabetes 
management.
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Appendix A 
List of excluding criteria (Castle, 2014) 
1. Female of childbearing potential who is pregnant or intending to become 
pregnant or breast-feeding, or is not using adequate contraceptive methods. 
Acceptable contraception includes birth control pill / patch / vaginal ring, 
Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a 
diaphragm and spermicide and the man uses a condom), or abstinence. 
2. Any cardiovascular disease, defined as a clinically significant EKG 
abnormality at the time of screening or any history of: stroke, heart failure, 
myocardial infarction, angina pectoris, or coronary arterial bypass graft or 
angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological 
arrhythmia judged by the investigator to be exclusionary. 
3. Renal insufficiency (GFR < 60 ml/min, using the MDRD equation as report by 
the OHSU laboratory). 
4. Impaired liver function, defined as AST or ALT ≥2.5 times upper limit of 
normal, according to OHSU laboratory reference ranges.  
5. Hematocrit of less than or equal to 34%. 
6. History of severe hypoglycemia during the past 12 months prior to screening 
visit or hypoglycemia unawareness as judged by the investigator.  
7. Adrenal insufficiency. 
8. Any active infection. 
9. Known or suspected abuse of alcohol, narcotics, or illicit drugs.  
10. Seizure disorder. 
11. Active foot ulceration. 
12. Severe peripheral arterial disease characterized by ischemic rest pain or severe 
claudication. 
13. Major surgical operation within 30 days prior to screening. 
14. Use of an investigational drug within 30 days prior to screening. 
15. Chronic usage of any immunosuppressive medication (such as cyclosporine, 
azathioprine, sirolimus, or tacrolimus). 
16. Bleeding disorder, treatment with warfarin, or platelet count below 50,000. 
17. Allergy to aspart insulin. 
18. Allergy to glucagon. 
19. Insulin resistance requiring more than 200 units per day. 
20. Need for uninterrupted treatment of acetaminophen. 
21. Current administration of oral or parenteral corticosteroids. 
22. Any life threatening disease, including malignant neoplasms and medical 
history of malignant neoplasms within the past 5 years prior to screening 
(except basal and squamous cell skin cancer).  
23. C peptide level of ≥0.5 ng/ml  
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24. Any concurrent illness, other than diabetes, that is not controlled by a stable 
therapeutic regimen. 
25. Beta blockers or non-dihydropyridine calcium channel blockers. 
26. A positive response to any of the questions from the Physical Activity 
Readiness Questionnaire.   
27. Any clinically significant disease or disorder which in the opinion of the 
Investigator may jeopardize the subject’s safety or compliance with the 
protocol. 
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